Abingdon Health PLC - York, England-based lateral flow contract research and contract development & manufacturing organisation - Says subsidiary CS (Lifesciences) Ltd has won a 12-month contract with an unnamed global diagnostics company, due to begin in March. The contract provides revenue of just under GBP500,000 and will see CS (Lifesciences) carry out work relating to quality management systems and regulatory approvals.
Abingdon acquired CS (Lifesciences), a consultancy specialising in compliance requirements for international IVD and medical device markets, in August 2024.
Abingdon Chief Executive Officer Chris Yates says: "This contract win illustrates one aspect of Abingdon's service offering in the medical diagnostic sector and to the wider med-tech industry. Our full CDMO [contract development & manufacturing] service, offering services to an international customer base, has been enhanced by our recent acquisition of CS (Lifescience) Ltd."
Current stock price: 8.50 pence, up 6.3% in London on Wednesday afternoon
12-month change: down 17%
By Emily Parsons, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2025 Alliance News Ltd. All Rights Reserved.